TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

NCT04173585 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Bortezomib
DRUG: Gemtuzumab Ozogamicin

Sponsor

University Hospital Heidelberg

Collaborators

[object Object]